Citicoline (CDP-Choline)

Endogenous brain compound, dual-substrate cholinergic donor + Kennedy-pathway nucleotide — supplies both choline (for acetylcholine) and cytidine→uridine (for membrane phospholipid synthesis and synaptic remodeling), giving it a unique mechanism alpha-GPC cannot match. A-tier evidence in healthy adults at 250-500 mg/day for attention, working memory, and processing speed (Bruce 2014 adolescent boys, McGlade 2012/2019, Yurgelun-Todd Cognizin RCTs); A-tier in stroke recovery and vascular cognitive impairment (where the Rx evidence base lives). Excellent safety record across decades of clinical use — no analogue of the Korean alpha-GPC stroke signal. For Dylan: confirmed-in-use at 500 mg Cognizin daily in V4. Pairs cleanly with NAC, magnesium, PS, DHA, and ALCAR/alpha-GPC (with anti-double-dose caveats). The single best chronic cholinergic baseline a 20yo brain-priority MMA athlete with subconcussive impact exposure can take.

Citicoline is cytidine 5'-diphosphocholine — a naturally-occurring nucleotide-choline conjugate that is the rate-limiting intermediate of the Kennedy pathway (the de novo synthesis route for phosphatidylcholine, the dominant phospholipid in cell membranes, including all neuronal membranes).

1. Gut hydrolysis → two substrates absorbed separately

• Oral citicoline is rapidly hydrolyzed in the gut to free choline + free cytidine, both >90% absorbed.
• Plasma bioavailability is essentially complete; the intact citicoline molecule does not survive digestion (this is why "citicoline" and "CDP-choline" peak plasma levels are reported as choline + cytidine elevations, not parent compound).
• Both halves cross the BBB independently — choline via the choline transporter (CTL1/SLC44A1), cytidine deaminated to uridine in human plasma, and uridine crosses the BBB via concentrative nucleoside transporters (CNT2/SLC28A2). (Note: in rats, cytidine itself is the BBB-crossing form; in humans, the cytidine→uridine conversion is fast, so brain uridine is the functional currency.)

2. Choline arm → acetylcholine synthesis

• Choline + acetyl-CoA → acetylcholine via choline acetyltransferase (ChAT) in cholinergic neurons.
• Plasma choline peak from 500 mg citicoline: ~13.1 μmol/L (Gatti 1992, equimolar IM head-to-head vs alpha-GPC's ~25.8 μmol/L). At equivalent oral doses citicoline produces roughly half the acute plasma choline bump that alpha-GPC does — the trade-off is that citicoline brings the cytidine/uridine arm that alpha-GPC lacks.
• Acetylcholine drives attention, vigilance, working memory, and (via M1/M3 muscarinic + α7 nicotinic) hippocampal synaptic plasticity.

3. Cytidine→uridine arm → Kennedy pathway membrane synthesis

• The Kennedy pathway: choline → phosphocholine → CDP-choline → phosphatidylcholine (the membrane phospholipid). The rate-limiting step is CTP:phosphocholine cytidylyltransferase (CCT), which requires CTP (cytidine triphosphate). Free cytidine/uridine in the brain feeds the CTP pool.
• Uridine specifically — and the uridine that comes from supplemental citicoline — has been shown by Wurtman's MIT lab to increase brain phosphatidylcholine, phosphatidylethanolamine, and synaptic protein content (PSD-95, synapsin-1) in animal models, with translation to synaptic-density and dendritic-spine increases. This is the molecular substrate of "synaptogenesis" — uridine + DHA + choline is the canonical triad in the Souvenaid (Fortasyn Connect) Alzheimer's nutritional intervention based on Wurtman's work.
• This is the citicoline-distinctive mechanism: alpha-GPC contributes choline to the Kennedy pathway but supplies no cytidine (the rate-limiting nucleotide). Citicoline is the only common choline supplement that provides both halves of the equation.

4. Dopaminergic effects

• Citicoline upregulates dopamine D1 and D2 receptor density in striatum and prefrontal cortex (animal data; replicated). Likely contributes to its mood/motivation/anhedonia signal in cocaine-use-disorder trials and to the subjective "drive" component reported by some users.
• Some data suggests modest tyrosine-hydroxylase activation, increasing dopamine synthesis. Effect size is modest relative to direct DA agents.

5. Anti-apoptotic / neuroprotective effects (stroke/ischemia mechanism)

• Citicoline preserves cardiolipin and sphingomyelin in mitochondrial membranes during ischemic injury, reduces phospholipase A2 activation, attenuates free-fatty-acid release, and inhibits the apoptotic cascade. This is the mechanistic basis for its stroke-recovery indication.
• Increases glutathione synthesis and reduces oxidative stress markers in ischemic tissue.

6. NGF/BDNF and growth-factor effects

• Some preclinical data shows modest BDNF/NGF upregulation, though smaller effect than dedicated neurotrophic compounds (Cerebrolysin, Semax, BPC-157).